INM — Mentari Therapeutics Share News
0.000.00%
Last trade - 00:00NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM
Brief: Inmed Pharmaceuticals Inmed Shareholders Are Expected To Own Approximately 1.51% Of Combined Company
NASDAQ RESUMED AT 08:25 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
Focus: Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification
Brief: InMed Pharmaceuticals Inc - On March 4, Co Confirmed And Approved The Decision To Wind Down Baymedica's Commercial Operations - SEC Filing
Advisory: Dated alerts on InMed Pharmaceuticals withdrawn
Brief: Inmed Pharmaceuticals Enters Agreement To Sell 1.9 Million Shares At $2.561 Each
Brief: Inmed Pharmaceuticals Inc Amends Standby Equity Purchase Agreement With Yorkville
Brief: InMed’S INM-901 Demonstrates Statistically Significant Reduction In Neuroinflammation In Long-Term Preclinical Alzheimer’S Disease Study
Brief: InMed Pharmaceuticals Files For Offering Of 3 Million Common Shares By Selling Stockholder
Brief: InMed Pharmaceuticals Receives Nasdaq Delisting Notice, Confirms It Has Filed Appeal & Obtained Panel Hearing Date
Brief: Inmed Pharmaceuticals Says On Feb 8, Board Appointed N. Netta "Neeta" Jagpal To Serve, As CFO & Corporate Secretary, Effective As Of Feb 20, 2024
Brief: Inmed Pharmaceuticals Announces Launch Of Inm-089
Brief: Inmed Pharmaceuticals Inc Files For Resale Of Up To 12.6 Million Shares Of Common Stock By The Selling Shareholders - SEC Filing
Brief: Inmed Pharmaceuticals' Inm-901 Demonstrates Unique Pharmacological Effects In Alzheimer's Disease In Preclinical Proof-Of-Concept Studies
Brief: InMed Pharmaceuticals Says On September 19, Received Written Notice From The Listing Qualifications Department Staff Of The Nasdaq Capital Market
Brief: Inmed Provides Update On Baymedica Rare Cannabinoid Business
Brief: InMed Reports Second Quarter Fiscal 2023 Financial Results